Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC) | Zendy

Fernando Cotait Maluf | Zendy; Felipe Moraes Toledo Pereira | Zendy; Pedro Luiz Serrano Usón | Zendy; Diogo Assed Bastos | Zendy; Diogo Augusto Rodrigues da Rosa | Zendy; Evanius Garcia Wiermann | Zendy; Fabio A.B. Schutz | Zendy; Fabio Kater | Zendy; Fernando Nunes Galvão de Oliveira | Zendy; Fernando Sabino Marques Monteiro | Zendy; Fernando Vidigal Pádua | Zendy; Francisco Orlandi | Zendy; Helena Paes de Almeida Saito | Zendy; Mouna Ayadi | Zendy; Pamela Salman Boghikian | Zendy; Ray Manneh Kopp | Zendy; Ricardo Saraiva de Carvalho | Zendy; Rodrigo Nogueira Fogace | Zendy; Sandro Roberto de Araújo Cavalléro | Zendy; Sergio Aguiar | Zendy; Vinícius Carrera Souza | Zendy; Silke Gillessen | Zendy

Open Access

Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)

Author(s) -

Fernando Cotait Maluf,

Felipe Moraes Toledo Pereira,

Pedro Luiz Serrano Usón,

Diogo Assed Bastos,

Diogo Augusto Rodrigues da Rosa,

Evanius Garcia Wiermann,

Fabio A.B. Schutz,

Fabio Kater,

Fernando Nunes Galvão de Oliveira,

Fernando Sabino Marques Monteiro,

Fernando Vidigal Pádua,

Francisco Orlandi,

Helena Paes de Almeida Saito,

Mouna Ayadi,

Pamela Salman Boghikian,

Ray Manneh Kopp,

Ricardo Saraiva de Carvalho,

Rodrigo Nogueira Fogace,

Sandro Roberto de Araújo Cavalléro,

Sergio Aguiar,

Vinícius Carrera Souza,

Silke Gillessen

Publication year - 2021

Publication title -

jco global oncology

Language(s) - English

Resource type - Journals

ISSN - 2687-8941

DOI - 10.1200/go.20.00505

Subject(s) - medicine , prostate cancer , docetaxel , androgen deprivation therapy , abiraterone acetate , regimen , guideline , oncology , prednisone , consensus conference , intensive care medicine , cancer , pathology

International guideline recommendations may not always be extrapolated to developing countries where access to resources is limited. In metastatic castration-sensitive prostate cancer (mCSPC), there have been successful drug and imaging advancements that were addressed in the Prostate Cancer Consensus Conference for Developing Countries for best-practice and limited-resource scenarios.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research